Article ; Online: Recent advances in lentiviral vector development and applications.
Molecular therapy : the journal of the American Society of Gene Therapy
2010 Volume 18, Issue 3, Page(s) 477–490
Abstract: Lentiviral vectors (LVs) have emerged as potent and versatile vectors for ex vivo or in vivo gene transfer into dividing and nondividing cells. Robust phenotypic correction of diseases in mouse models has been achieved paving the way toward the first ... ...
Abstract | Lentiviral vectors (LVs) have emerged as potent and versatile vectors for ex vivo or in vivo gene transfer into dividing and nondividing cells. Robust phenotypic correction of diseases in mouse models has been achieved paving the way toward the first clinical trials. LVs can deliver genes ex vivo into bona fide stem cells, particularly hematopoietic stem cells, allowing for stable transgene expression upon hematopoietic reconstitution. They are also useful to generate induced pluripotent stem cells. LVs can be pseudotyped with distinct viral envelopes that influence vector tropism and transduction efficiency. Targetable LVs can be generated by incorporating specific ligands or antibodies into the vector envelope. Immune responses toward the transgene products and transduced cells can be repressed using microRNA-regulated vectors. Though there are safety concerns regarding insertional mutagenesis, their integration profile seems more favorable than that of gamma-retroviral vectors (gamma-RVs). Moreover, it is possible to minimize this risk by modifying the vector design or by employing integration-deficient LVs. In conjunction with zinc-finger nuclease technology, LVs allow for site-specific gene correction or addition in predefined chromosomal loci. These recent advances underscore the improved safety and efficacy of LVs with important implications for clinical trials. |
---|---|
MeSH term(s) | Animals ; Gene Transfer Techniques ; Genetic Therapy/methods ; Genetic Vectors ; Hematopoietic Stem Cells/cytology ; Humans ; Lentivirus/genetics ; Ligands ; Models, Genetic ; Mutagenesis ; Phenotype ; Pluripotent Stem Cells/cytology ; Retroviridae/genetics ; Risk ; Transgenes |
Chemical Substances | Ligands |
Language | English |
Publishing date | 2010-01-19 |
Publishing country | United States |
Document type | Journal Article ; Research Support, Non-U.S. Gov't ; Review |
ZDB-ID | 2010592-7 |
ISSN | 1525-0024 ; 1525-0016 |
ISSN (online) | 1525-0024 |
ISSN | 1525-0016 |
DOI | 10.1038/mt.2009.319 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5640: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.